These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36150672)

  • 1. Macrolide therapy in Pseudomonas aeruginosa infections causes uL4 ribosomal protein mutations leading to high-level resistance: author's response.
    Goltermann L; Johansen HK; Molin S; La Rosa R
    Clin Microbiol Infect; 2022 Dec; 28(12):1667-1668. PubMed ID: 36150672
    [No Abstract]   [Full Text] [Related]  

  • 2. Macrolide therapy in Pseudomonas aeruginosa infections causes uL4 ribosomal protein mutations leading to high-level resistance.
    Goltermann L; Andersen KL; Johansen HK; Molin S; La Rosa R
    Clin Microbiol Infect; 2022 Dec; 28(12):1594-1601. PubMed ID: 35988850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: 'Macrolide therapy in Pseudomonas aeruginosa infections causes uL4 ribosomal protein mutations leading to high-level resistance' by Goltermann et al.
    Karakonstantis S
    Clin Microbiol Infect; 2022 Dec; 28(12):1665-1666. PubMed ID: 36075497
    [No Abstract]   [Full Text] [Related]  

  • 4. [Quorum-sensing system of Pseudomonas aeruginosa--a novel target for antibacterial agents].
    Tateda K; Ishii Y; Yamaguchi K
    Nihon Saikingaku Zasshi; 2004 Nov; 59(4):543-9. PubMed ID: 15646084
    [No Abstract]   [Full Text] [Related]  

  • 5. [Antipseudomonic effect of macrolides. Experience in a case of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa without response to antibiotic therapy].
    Barbero JM; Arranz A; Rebollar A; Culebras A; García M; Agudo R; Pérez L; Montero E
    Rev Esp Quimioter; 2018 Feb; 31(1):72-74. PubMed ID: 29390604
    [No Abstract]   [Full Text] [Related]  

  • 6. Characterization of Two Macrolide Resistance-Related Genes in Multidrug-Resistant
    Chen Q; Lu W; Zhou D; Zheng G; Liu H; Qian C; Zhou W; Lu J; Ni L; Bao Q; Li A; Xu T; Xu H
    Pol J Microbiol; 2020 Sep; 69(3):349-356. PubMed ID: 33574864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors.
    Tateda K; Standiford TJ; Pechere JC; Yamaguchi K
    Curr Pharm Des; 2004; 10(25):3055-65. PubMed ID: 15544497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in ribosomal proteins and ribosomal RNA confer macrolide resistance in human Ureaplasma spp.
    Xiao L; Crabb DM; Duffy LB; Paralanov V; Glass JI; Hamilos DL; Waites KB
    Int J Antimicrob Agents; 2011 Apr; 37(4):377-9. PubMed ID: 21353494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.
    Murray TS; Egan M; Kazmierczak BI
    Curr Opin Pediatr; 2007 Feb; 19(1):83-8. PubMed ID: 17224667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired resistance to macrolides in
    Mustafa MH; Khandekar S; Tunney MM; Elborn JS; Kahl BC; Denis O; Plésiat P; Traore H; Tulkens PM; Vanderbist F; Van Bambeke F
    Eur Respir J; 2017 May; 49(5):. PubMed ID: 28526799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004).
    Wierzbowski AK; Nichol K; Laing N; Hisanaga T; Nikulin A; Karlowsky JA; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2007 Oct; 60(4):733-40. PubMed ID: 17673477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
    Tramper-Stranders GA; Wolfs TF; Fleer A; Kimpen JL; van der Ent CK
    Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribosomal mutations as the main cause of macrolide resistance in Campylobacter jejuni and Campylobacter coli.
    Lehtopolku M; Kotilainen P; Haanperä-Heikkinen M; Nakari UM; Hänninen ML; Huovinen P; Siitonen A; Eerola E; Jalava J; Hakanen AJ
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5939-41. PubMed ID: 21911571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Airway biofilms: implications for pathogenesis and therapy of respiratory tract infections.
    Kobayashi H
    Treat Respir Med; 2005; 4(4):241-53. PubMed ID: 16086598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia.
    Laserna E; Sibila O; Fernandez JF; Maselli DJ; Mortensen EM; Anzueto A; Waterer G; Restrepo MI
    Chest; 2014 May; 145(5):1114-1120. PubMed ID: 24458223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inability of L22 ribosomal protein alteration to increase macrolide MICs in the absence of efflux mechanism in Haemophilus influenzae HMC-S.
    Peric M; Bozdogan B; Galderisi C; Krissinger D; Rager T; Appelbaum PC
    J Antimicrob Chemother; 2004 Aug; 54(2):393-400. PubMed ID: 15243030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrolide Resistance in
    Schroeder MR; Stephens DS
    Front Cell Infect Microbiol; 2016; 6():98. PubMed ID: 27709102
    [No Abstract]   [Full Text] [Related]  

  • 18. High levels of macrolide resistance-associated mutations in Mycoplasma genitalium warrant antibiotic susceptibility-guided treatment.
    Nijhuis RH; Severs TT; Van der Vegt DS; Van Zwet AA; Kusters JG
    J Antimicrob Chemother; 2015 Sep; 70(9):2515-8. PubMed ID: 25995292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibility and mechanisms of high-level macrolide resistance in clinical isolates of Moraxella nonliquefaciens.
    Nonaka S; Matsuzaki K; Kazama T; Nishiyama H; Ida Y; Koyano S; Sonobe K; Okamura N; Saito R
    J Med Microbiol; 2014 Feb; 63(Pt 2):242-247. PubMed ID: 24196134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
    Sugimura M; Maseda H; Hanaki H; Nakae T
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4141-4. PubMed ID: 18676884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.